Rebecca E. Jimenez

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy”.

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2019-000438

N/A

0DataRank · unranked

191 citations

Shumei Kato, Suzanna Lee, Rebecca E. Jimenez, Jason K. Sicklick, Razelle Kurzrock +1 more

Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3761

N/A

0DataRank · unranked

41 citations

Jacob J. Adashek, Justin Shaya, Ryosuke Okamura, Rebecca E. Jimenez, Suzanna Lee +3 more

High prevalence of clonal hematopoiesis‐type genomic abnormalities in cell‐freeDNAin invasive gliomas after treatment

International Journal of Cancer(2021)10.1002/ijc.33481

N/A

0DataRank · unranked

31 citations

David Piccioni, Amélie Boichard, Suzanna Lee, Rebecca E. Jimenez, Jason K. Sicklick +3 more

Data from Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics

(2023)10.1158/1078-0432.c.6529977

N/A

0DataRank · unranked

0 citations

Jacob J. Adashek, Justin Shaya, Ryosuke Okamura, Rebecca E. Jimenez, Suzanna Lee +3 more